Çetin Ordu1, Kezban Nur Pilancı2, Gül Alço1, Filiz Elbüken1, Ülkühan İner Köksal1, Serkan İlgun3, Dauren Sarsenov4, Ayşe Esra Aydın4, Alper Öztürk5, Zeynep İyigün Erdoğan6, Filiz Ağaçayak4, Fatmagül Çubuk3, Coşkun Tecimer1, Yeşim Eralp7, Tomris Duymaz8, Fatma Aktepe1, Vahit Özmen7. 1. Department of Medical Oncology, Gayrettepe Florence Nightingale Hospital, İstanbul, Turkey. 2. Department of Medical Oncology, Haseki Research and Training Hospital, İstanbul, Turkey. 3. Department of General Surgery, Gaziosmanpaşa Research and Training Hospital, İstanbul, Turkey. 4. Department of Breast Surgery, Istanbul Florence Nightingale Hospital, İstanbul, Turkey. 5. Department of General Surgery, Biruni University, İstanbul, Turkey. 6. Department of Physical Therapy and Rehabilitation, Şişli Florence Nightingale Hospital, İstanbul, Turkey. 7. Department of Medical Oncology, Istanbul University School of Medicine, İstanbul, Turkey. 8. Department of Physical Therapy and Rehabilitation, İstanbul Bilim University, İstanbul, Turkey.
Abstract
OBJECTIVE: In this retrospective study, chemotherapy induced amenorrhea in patients with early stage breast cancer and its effects on survival were investigated. MATERIALS AND METHODS: Two hundred fifty-two patients received adjuvant chemotherapy without ovarian suppression treatment (OST) from 600 premenopausal patients were included in the study. Patients were divided into two groups; with amenorrhea and without, and compared with clinicopathologic features and survival. SPSS version 17 was used. RESULTS: Chemotherapy-induced amenorrhea (CIA) was observed in 145 (57.5%) of 252 patients who received no OST during follow-up. The 5-year OS rate of patients with CIA was significantly higher than patients without CIA (p= 0.042, 95.9% vs. 89.7% vs. 158.88 vs. 135.33 months, respectively). In the subgroup analysis, the OS in patients with hormone receptor (+) was significantly higher than in those receptor (-) in patients with CIA (p=0.011, 97.5% vs. 90.9% vs. 162.13 vs. 126.16 months, respectively). The OS was significantly longer in the luminal A molecular subtype than in those with luminal B molecular subtype, in patients with CIA, but the difference was not significant in patients without CIA (p=0.027 vs. p=0.074, respectively). CONCLUSION: As a conclusion; survival advantage of the chemotherapy induced amenorrhea more pronounced with hormone receptor positivity, lymph node involvement, and advanced disease over patients who do not develop amenorrhea. This advantage of amenorrhea development further prolongs survival compared with luminal B in the luminal A molecular subtype.
OBJECTIVE: In this retrospective study, chemotherapy induced amenorrhea in patients with early stage breast cancer and its effects on survival were investigated. MATERIALS AND METHODS: Two hundred fifty-two patients received adjuvant chemotherapy without ovarian suppression treatment (OST) from 600 premenopausal patients were included in the study. Patients were divided into two groups; with amenorrhea and without, and compared with clinicopathologic features and survival. SPSS version 17 was used. RESULTS: Chemotherapy-induced amenorrhea (CIA) was observed in 145 (57.5%) of 252 patients who received no OST during follow-up. The 5-year OS rate of patients with CIA was significantly higher than patients without CIA (p= 0.042, 95.9% vs. 89.7% vs. 158.88 vs. 135.33 months, respectively). In the subgroup analysis, the OS in patients with hormone receptor (+) was significantly higher than in those receptor (-) in patients with CIA (p=0.011, 97.5% vs. 90.9% vs. 162.13 vs. 126.16 months, respectively). The OS was significantly longer in the luminal A molecular subtype than in those with luminal B molecular subtype, in patients with CIA, but the difference was not significant in patients without CIA (p=0.027 vs. p=0.074, respectively). CONCLUSION: As a conclusion; survival advantage of the chemotherapy induced amenorrhea more pronounced with hormone receptor positivity, lymph node involvement, and advanced disease over patients who do not develop amenorrhea. This advantage of amenorrhea development further prolongs survival compared with luminal B in the luminal A molecular subtype.
Entities:
Keywords:
Chemotherapy-induced amenorrhea; breast cancer; molecular subtypes; survival
Authors: Henri Roché; Pierre Fumoleau; Marc Spielmann; Jean-Luc Canon; Thierry Delozier; Daniel Serin; Michel Symann; Pierre Kerbrat; Patrick Soulié; Françoise Eichler; Patrice Viens; Alain Monnier; Anita Vindevoghel; Mario Campone; Marie-Josèphe Goudier; Jacques Bonneterre; Jean-Marc Ferrero; Anne-Laure Martin; Jean Genève; Bernard Asselain Journal: J Clin Oncol Date: 2006-11-20 Impact factor: 44.544
Authors: Wendy R Parulekar; Andrew G Day; Jon A Ottaway; Lois E Shepherd; Maureen E Trudeau; Vivien Bramwell; Mark Levine; Kathleen I Pritchard Journal: J Clin Oncol Date: 2005-09-01 Impact factor: 44.544
Authors: Marco Colleoni; Shari Gelber; Aron Goldhirsch; Stefan Aebi; Monica Castiglione-Gertsch; Karen N Price; Alan S Coates; Richard D Gelber Journal: J Clin Oncol Date: 2006-02-27 Impact factor: 44.544
Authors: Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis Journal: N Engl J Med Date: 2014-06-01 Impact factor: 91.245
Authors: A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn Journal: Ann Oncol Date: 2013-08-04 Impact factor: 32.976